Modified Immune Cells with Adenosine Deaminase Base Editors for Gene Editing
Summary
USPTO granted Patent US12600971B2 to Beam Therapeutics Inc. covering genetically modified immune cells incorporating adenosine base editors (ABE8) for modifying nucleobases in target sequences. The patent contains 22 claims and was filed on February 13, 2020, under Application No. 17430676.
What changed
USPTO granted Patent US12600971B2 to Beam Therapeutics Inc. covering compositions and methods for genetically modified immune cells comprising adenosine deaminase base editors (specifically ABE8 variants) that provide enhanced anti-neoplasia activity, resistance to immune suppression, and reduced risk of graft-versus-host or host-versus-graft reactions. The patent protects both the modified immune effector cells and methods for producing and using them.
Biotechnology companies engaged in gene editing, cell therapy, and cancer immunotherapy development should evaluate this patent for freedom-to-operate considerations and potential licensing opportunities. The granted patent may affect competitive positioning in the base editor and CAR-T adjacent technology space.
What to do next
- Review patent claims for freedom-to-operate implications
- Assess licensing opportunities for immune cell gene editing technology
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
Grant US12600971B2 Kind: B2 Apr 14, 2026
Assignee
BEAM THERAPEUTICS INC.
Inventors
Nicole Gaudelli, Michael Packer, Ian Slaymaker, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Jason M. Gehrke
Abstract
The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
CPC Classifications
C12N 9/222
Filing Date
2020-02-13
Application No.
17430676
Claims
22
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.